The Next Cancer Bestseller?

Langreth, Robert
May 2009
Forbes Asia;5/11/2009, Vol. 5 Issue 8, p48
The article presents information on Afinitor, kidney cancer drug from Novartis AG. Afinitor was approved in March 2009 for patients with advanced kidney cancer who failed other treatments. Novartis plans to test Afinitor simultaneously on five other tumor types, including breast, stomach, and neuroendocrine tumor. A trial on 416-patient led by oncologist Robert Motzer found that Afinitor delayed disease progression in patients with kidney cancer by three months.


Related Articles

  • Denosumab in Oncology: Two Down, Whopper to Go. Morrison, Trista // BioWorld Today;8/5/2009, Vol. 20 Issue 149, p3 

    The article reports on the achievement of the primary endpoint by Amgen Incorporated's denosumab in its second Phase III oncology trial. Earlier, the drug showed superiority to Novartis AG's Zometa or zoledronic acid in advanced breast cancer patients with bone metastases. The delay of...

  • Breast Cancer Update.  // PharmaWatch: Cancer;May2006, Vol. 5 Issue 5, p14 

    The article reports on developments related to breast cancer drug manufacturing. GlaxoSmithKline PLC has ended its phase III clinical trial of Tykerb after the drug achieved statistical significance in helping women with advanced breast cancer. Femara of Novartis AG was designed to improve...

  • Breast Cancer Update.  // PharmaWatch: Cancer;Jun2007, Vol. 6 Issue 6, p7 

    The article offers news briefs related to breast cancer treatment. Bionovo Inc. has started its phase I/II clinical trial of its drug candidate for the treatment of women with advanced breast cancer. Novartis AG has reported that its breast cancer drug Femara reduces the risk of the disease...

  • San Antonio Breast Cancer Symposium.  // BioWorld Today;12/9/2011, Vol. 22 Issue 237, p7 

    The article deals with the results presented by Novartis AG at the 2011 San Antonio Breast Cancer Symposium from its Phase III BOLERO-2 study of Afinitor tablets plus exemestane in women with advanced breast cancer.

  • Researchers terminate trial examining aliskiren in high-risk patients.  // Cardiology Today;Jan2012, Vol. 15 Issue 1, p20 

    The article reports on the termination by Novartis of a clinical trial examining the safety and efficacy of aliskiren in treating hypertension in high-risk patients with type 2 diabetes and renal impairment.

  • A place in the sun. Abbott, Alison // Nature;3/8/2007, Vol. 446 Issue 7132, p124 

    The article features the Sclavo Institute in Siena, Italy, the laboratory that is the center of the development of vaccines by Swiss drug company Novartis. The company acquired a broad portfolio of vaccine candidates when it purchased California biotechnology firm Chiron in April 2006. Half-a...

  • Pharma: Clinic Roundup.  // BioWorld Today;12/21/2012, Vol. 23 Issue 247, p9 

    The article reports on the results of clinical trials in the biopharmaceutical industry including the primary endpoint missed in Merck and Co. Inc.'s study of Tredaptive and the study by Novartis AG of its ACZ885 compound for systematic juvenile idiopathic arthritis.

  • Pharma: Clinic Roundup.  // BioWorld Today;4/26/2012, Vol. 23 Issue 81, p8 

    This section offers news briefs on clinical trials including the results reported by Novartis AG from a Phase III study of the Exelon Patch in patients with Alzheimer's diease and improvements exhibited by UCB SA's Neupro in treating patients with restless legs syndrome in trials.

  • Novartis gets good heart-drug news. Weinstein, Deborah // Medical Marketing & Media;May2014, Vol. 49 Issue 5, p12 

    The article reports on the results of the clinical trial by pharmaceutical company Novartis AG on its heart failure drug LCZ696 which revealed that the drug is very effective, prompting an independent data monitoring committee to recommend to stop the trial.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics